Skip to main content

Table 2 Association of Baseline Blood Biomarkers and Outcomes

From: Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies

  Multivariate Model for PFS   Multivariate Model for OS  
Biomarker HR (95% CI)a, N = 157 P Valuea HR (95% CI)a, N = 157 P Valuea
WBC 1.01 (0.97–1.05) .68 1.04 (0.99–1.09) .10
ANC 1.01 (0.97–1.06) .55 1.04 (1.00–1.09) .08
ANC ≥ 7.5 1.05 (0.68–1.63) .81 1.86 (1.09–3.19) .02
ALC 0.78 (0.56–1.10) .15 0.86 (0.56–1.31) .48
ANC/ALC 1.04 (1.02–1.06) <.001 1.04 (1.02–1.06) <.001
ANC/ALC ≥ 5.9 1.61 (1.14–2.28) .008 1.87 (1.16–3.02) .01
AMC ≥ 0.63 1.50 (1.06–2.12) .02 1.59 (0.88–2.90) .13
AEC 0.43 (0.15–1.29) .13 1.71 (1.06–2.75) <.03
Platelets (per 50 unit increase) 1.03 (0.95–1.11) .48 0.29 (0.06–1.55) .15
M:L 1.04 (1.02–1.06) <.001 1.05 (0.95–1.15) .34
M:L ≥ 11.3 1.36 (0.91–2.03) .13 1.04 (1.02–1.06) <.001
  1. aHRs, 95% CI, and P values result from single variable (ie, unadjusted) Cox proportional hazard models. Multivariable models were adjusted for age at diagnosis, sex, ECOG, and number of lines of chemotherapy for OS; adjusted for age at diagnosis and sex for PFS